gmp
gmp

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Valbiotis

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EXTRACTABLES & LEACHABLES SUMMIT

              Participation Not Confirmed

              Update your events

              VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia

              Contact the Supplier

              Lead Product(s): TOTUM-070

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-070

              Highest Development Status: Phase I/ Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 14, 2020

              Details:

              TOTUM-070 is a combination of plant extracts that contains neither phytosterols nor red yeast rice, designed by VALBIOTIS’ proprietary R&D platform based in Riom (63).

              Valbiotis

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EXTRACTABLES & LEACHABLES SUMMIT

              Participation Not Confirmed

              Update your events

              VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction

              Contact the Supplier

              Lead Product(s): TOTUM-070

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 16, 2020

              Details:

              VALBIOTIS expects to start a Phase II clinical trial evaluating the effect of TOTUM-070 in reducing LDL-cholesterol, in mild to moderate hypercholesterolemic patients.

              PharmaCompass__DigitalAd